Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554

Phase 2CFTX-1554Positive

AI Analysis

Summary

Eli Lilly has initiated a Phase 2a clinical trial for CFTX-1554, a peripheral pain candidate developed by Confo Therapeutics. The trial represents a key development milestone in the collaboration between the two companies.

Clinical Trial Data

Phase

Importance:6/10

Sentiment:

0.60

Phase 2 initiationperipheral painpartnershipclinical trial

Related Companies

$LLY

Read the original article

Published by GlobeNewswire Clinical Studies on April 30, 2026 3:30 PM

Read Original